Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Adam is at it again: RTQ: 8.95 down 95 cents. There's more turmoil to report at struggling XBiotech (XBIT) . The biotech company's No. 2 executive resigned last week.
Kelly Thornburg, XBiotech's senior vice president of operations, submitted his resignation letter on May 5 and left the company immediately. Thornburg's exit was disclosed in a note at the bottom of the XBiotech 10-Q filed with the Securities and Exchange Commission on Wednesday night.
Feuerstein Is a JOKE!!! Has as many bad calls as good.. He himself is a great pumper/basher with his articles and tweets.. And I took a position on the drop for a swing trade ... G/L
BIOTECH STOCKS WORTH CHASING: XBIOTECH, INC. (XBIT), ELEVEN BIOTHERAPEUTICS, INC. (EBIO)
XBiotech, Inc. (XBIT) ended last trading session with a change of 19.02 percent. It trades at an average volume of 198.66K shares versus 1.07M shares recorded at the end of last trading session. The share price of $24.9 is at a distance of 291.51 percent from its 52-week low and down 14.22 percent versus its peak. The company has a market cap of $676.78M and currently has 27.18M shares outstanding. The share price is currently 42.66 percent versus its SMA20, 64.26 percent versus its SMA50, and 104.68 percent versus its SMA200. The stock has a weekly performance of 37.11 percent and is 129.07 percent year-to-date as of the recent close.
On July 02, 2016 XBiotech Inc. (XBIT) presented positive results from a pivotal Phase III trial of Xilonix™, the company’s lead monoclonal (IgG1k) antibody immunotherapy for the treatment of advanced colorectal cancer (CRC). In the study, Xilonix-treated patients with advanced disease and multiple symptoms known to inversely correlate with overall survival experienced a 76% relative increase in clinical response rate (CRR), a novel measure of anti-cancer activity, after 8 weeks of therapy compared to placebo (33% vs. 19%, respectively; p=.0045). In addition, clinical response correlated with improved overall survival. Among responders (in both treatment and placebo arms), clinical response was associated with a 2.7-fold increase in overall survival (11.5 versus 4.2 months in responders vs. non-responders, respectively). Overall survival was not compared between treatment arms because after 8 weeks, all patients were eligible to receive study drug. Treatment with Xilonix was well tolerated, with an adverse event profile comparable to placebo. The data were presented at the 18th European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona, Spain.
Eleven Biotherapeutics, Inc. (EBIO) recently recorded 12.57 percent change and currently at $1.88 is 649 percent away from its 52-week low and down -76.5 percent versus its peak. It has a past 5-day performance of -12.15 percent and trades at an average volume of 3.38M shares. The stock has a 1-month performance of 5.62 percent and is -37.54 percent year-to-date as of the recent close. There were about 19.64M shares outstanding which made its market cap $36.92M. The share price is currently -10.05 percent versus its SMA20, 25.55 percent versus its SMA50, and 12.08 percent versus its SMA200.
On June 13, 2016 Eleven Biotherapeutics, Inc. (EBIO) announced that it has entered into an exclusive license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) relating to Eleven’s Interleukin-6 (IL-6) technology. Under the terms of the agreement, Eleven has agreed to grant an exclusive, worldwide license to Roche to develop and commercialize EBI-031, a humanized monoclonal antibody that potently binds IL-6 and inhibits all known forms of IL-6 cytokine signaling, currently being developed for the potential treatment of ocular diseases, and all other IL-6 antagonist antibody technology owned by Eleven.
Worst timing---EVER Try to buy stocks that go up. That would be best. I looked at your buys and sells in your profile. Please let us know when you are ready to buy something else so we can all run away---FAST
Thu, 03 Sep 2015 18:25:05 GMT ~ XBiotech Advances Phase 1/2 Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus
[at noodls] - 0 1 09.01.15 - XBiotech Advances Phase 1/2 Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus Company Begins Second Dosing Cohort in Dose ...
Tue, 01 Sep 2015 11:00:00 GMT ~ XBiotech Advances Phase 1/2 Clinical Study of Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus Aureus
[GlobeNewswire] - AUSTIN, Texas -- XBiotech (NASDAQ:XBIT), the world's leading developer of next-generation True Human(TM) therapeutic antibodies, announced today the completion of the first cohort in its Phase 1/2 clinical ...
Mon, 17 Aug 2015 15:33:08 GMT ~ XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe
[at noodls] - 0 1 08.17.15 - XBiotech (NASDAQ: XBIT), the world's leading developer of next-generation True Human™ therapeutic antibodies, announced today it has completed enrollment of the Company's pivotal, randomized ...
Mon, 17 Aug 2015 11:00:00 GMT ~ XBiotech Completes Enrollment for Xilonix(TM) Phase III Registration Study in Europe
[GlobeNewswire] - AUSTIN, Texas -- XBiotech (NASDAQ:XBIT), the world's leading developer of next-generation True Human(TM) therapeutic antibodies, announced today it has completed enrollment of the Company's pivotal, randomized ...
Link: http://www.otcmarkets.com/stock/XBIT/company-info Ticker: $XBIT OTC Market Place: Not Available CIK code: not found Company name: XBiotech Inc. Incorporated In: $XBIT share structure
## source: otcmarkets.com
Market Value: Not Available Shares Outstanding: Not Available Float: Not Available Authorized Shares: Not Available Par Value: Not Available
XBiotech, Inc.
8201 East Riverside Drive
Suite 100
Austin, TX 78744
United States
Phone: 512-386-2900
Fax: 512-386-5505
Website: http://www.xbiotech.com
XBiotech, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing ‘True Human’ monoclonal antibodies for treating various different diseases. Its lead product is Xilonix, a novel anti-cancer agent, which has completed enrollment of its pivotal, randomized double-blinded placebo controlled Phase III study in Europe for the treatment of advanced colorectal cancer. Xilonix targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth, and spread of tumors, as well as mediate symptoms, such as metabolic dysregulation, fatigue, and anxiety associated with advanced cancer. The company also develops a proprietary True Human monoclonal antibody discovery platform and manufacturing system. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.